Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Mirxes Holding Company HK$1.09 billion IPO
We advised Mirxes on its IPO and HKEX listing
ADC Therapeutics $100 million private placement
We advised ADC Therapeutics on the equity offering
Omada Health $172.6 million IPO
The shares are listed on the Nasdaq Global Select Market
PegBio IPO
We advised PegBio on its IPO and HKEX listing
Hinge Health $503 million IPO
The shares are listed on the New York Stock Exchange
Kenvue $750 million senior notes offering
The investment-grade notes are due 2032
Atara Biotherapeutics registered direct offering
The stock is listed on Nasdaq
CytomX Therapeutics $100 million stock offering
The stock is listed on the Nasdaq Global Select Market
Auna $62.1 million senior secured notes offering
We advised Auna on the offering
Biogen $1.75 billion senior notes offering
The investment-grade notes are due 2031, 2035 and 2055